Drugs / CT-P41
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06037395 | Oct 2021 → Oct 2022 | — | Celltrion | Completed | No outcome recorded |
| Phase 1 | NCT04512872 | Oct 2020 → May 2021 | — | Celltrion | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04757376 | Jun 2021 → May 2023 | postmenopausal osteoporosis | Celltrion | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-P41 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04512872 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT04512872 ↗ |